Home > Gastroenterology > Adding thiopurines to vedolizumab has benefits in Crohn’s disease

Adding thiopurines to vedolizumab has benefits in Crohn’s disease


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
 Gut
Reuters Health - 15/04/2022 - For patients with Crohn's disease, combining thiopurines with vedolizumab may be more effective than vedolizumab alone, new findings suggest.  "Infliximab combined with thiopurines is more effective than infliximab monotherapy in inflammatory bowel disease (IBD), but the impact of adding thiopurines to vedolizumab remains controversial. No clinical trials are currently performed to address this question," researchers note in the journal Gut.  To investigate, they used two U.S. healthcare-claims database and the French nationwide healthcare database to identify nearly 10,300 patients with Crohn's disease (CD) or ulcerative colitis (...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on